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Abstract
Objectives: Continuous or bilevel positive airway pressure ventilation, called noninvasive ventilation
(NIV), is a controversial therapy for acute decompensated heart failure (ADHF). While NIV is considered
safe and effective in patients with chronic obstructive pulmonary disease (COPD), clinical trial data that
have addressed safety in ADHF patients are limited, with some suggestion of increased mortality. The
objective of this study was to assess mortality outcomes associated with NIV and to determine if a failed
trial of NIV followed by endotracheal intubation (ETI) (NIV failure) is associated with worse outcomes,
compared to immediate ETI.
Methods: This was a retrospective analysis of the Acute Decompensated Heart Failure National Registry
(ADHERE), which enrolls patients with treatment for, or with a primary discharge diagnosis of, ADHF.
The authors compared characteristics and outcomes in four groups: no ventilation, NIV success, NIV
failure, and ETI. One-way analysis of variance or Wilcoxon testing was performed for continuous data,
and chi-square tests were used for categorical data. In addition, multivariable logistic regression was
used to adjust mortality comparisons for risk factors.
Results: Entry criteria were met by 37,372 patients, of which 2,430 had ventilation assistance. Of the
ventilation group, 1,688 (69.5%) were deemed NIV success, 72 (3.0%) were NIV failures, and 670 (27.6%)
required ETI. The NIV failure group had the lowest O2 saturation (SaO2) (84 ± 16%), compared to either
NIV success (89.6 ± 10%) or ETI (88 ± 13%; p = 0.017). ETI patients were more likely to receive vaso-
active medications (p < 0.001) than the NIV success cohort. When comparing NIV failures to ETI, there
were no differences in treatment during hospitalization (p > 0.05); other than that the NIV failure group
more often received vasodilators (68.1% vs. 54.3%; p = 0.026). In-hospital mortality was 7.9% with NIV,
13.9% with NIV failure, and 15.4% with ETI. After risk adjustment, the mortality odds ratio for NIV
failure versus ETI increased to 1.43, although this endpoint was not statistically significant.
Conclusions: In this analysis of ADHF patients receiving NIV to date, patients placed on NIV for ADHF
fared better than patients requiring immediate ETI. Patients who failed NIV and required ETI still experi-
enced lower mortality than those initially placed on ETI. Thus, while the ETI group may be more
severely ill, starting therapy with NIV instead of immediate ETI will likely not harm the patient. When
ETI is required, mortality and length of stay may be adversely affected. Since a successful trial of NIV is
associated with improved outcomes in patients with ADHF, application of this therapy may be a reason-
able treatment option.
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N oninvasive ventilation (NIV) is an alternative todefinitive airway placement in emergencydepartment (ED) patients with acute dyspnea,
and while well established as beneficial in acute respira-
tory syndromes (e.g., chronic obstructive pulmonary dis-
ease [COPD]), its value in acute decompensated heart
failure (ADHF) is less clearly defined. Many studies
examine NIV as part of a generic respiratory syndromes
strategy (enrolling patients irrespective of their underly-
ing disease state, e.g., COPD, pneumonia, ADHF), and
several meta-analyses1,2 have specifically reported on
NIV in ADHF. However, to our knowledge, only one
ADHF data set describing NIV safety or efficacy includes
more than 300 patients. Consequently, safety, clinical
outcomes, and mortality rates associated with NIV in
ADHF are unclear.
Noninvasive ventilation is commonly defined as
adjunctive airway support in lieu of endotracheal intu-
bation (ETI) and is used as either continuous positive
airway pressure (CPAP) or intermittent biphasic posi-
tive airway pressure (BiPAP).3–5 It is pressure-con-
trolled ventilation delivered by a mask that allows
unrestricted spontaneous breathing any time in the
ventilatory cycle. CPAP is delivered by a mask that
completely covers the face, inclusive of both the nose
and the mouth. BiPAP may also be administered by a
full face mask, but also has the option of a delivery sys-
tem that covers only the nasal passages, leaving the
mouth open. CPAP provides expiratory support,
whereas BiPAP provides inspiratory and expiratory
support. With BiPAP, the patient must be able to coor-
dinate their breathing cycle, closing their mouth during
positive air pressure delivery; otherwise air will flow
into the nares and out of the mouth, rather than being
delivered to the lungs.
Noninvasive ventilation is used to provide temporary
oxygenation and ventilation for respiratory distress and
is not a definitive solution for airway control. As such,
it is a temporizing alternative to immediate ETI and is
used to provide time for other interventions (e.g., vaso-
dilators for ADHF) to become effective. NIV is limited
by the requirements of a mentally able and cooperative
patient, with anatomy that allows an adequate facemask
seal.
Since many small studies and anecdotal reports sug-
gest benefit with NIV, it is commonly employed in the
ED.6 Masip et al.1 evaluated NIV for ADHF. In this 15-
study meta-analysis of 389 patients receiving NIV for
acute pulmonary edema, mortality and the need for
intubation were reduced. While meta-analyses may pro-
vide insight if the literature is without large data sets or
randomized controlled trials, their weaknesses are well
described, including that of Simpson’s paradox7 (where
an erroneous conclusion is reached due to an unknown
variable).
The literature regarding outcomes of NIV for ADHF is
not uniform. In a pooled systematic review of ADHF and
NIV, Pang et al.8 reported that CPAP resulted in a 6.6%
mortality decrease, but the confidence intervals (CIs)
included a potential 3% mortality increase. Others have
reported increased rates of ETI, acute myocardial infarc-
tion, and mortality when BiPAP is used in ADHF.9,10
Although limited by sample size, another meta-analysis
pointed out that ‘‘weak evidence of an increase in the
incidence of new myocardial infarction with bilevel
ventilation versus CPAP was recorded.’’2 Most data
were collected as one category, ‘‘use of bipap ⁄ cpap,’’ so
a distinction between the two cannot be made.
The largest analysis of the use of NIV in the ED for
cardiogenic pulmonary edema is a 494-patient system-
atic review by Collins et al.11 Based on MEDLINE, The
Excerpta Medica Database (EMBASE), and the Cochra-
ne Library data from 1980 to 2005, they concluded that
NIV is advantageous in ED patients with acute pulmo-
nary edema. This pooled analysis concluded that when
NIV is added to standard medical therapy, hospital
mortality is reduced.
The purpose of our study was to determine patient
outcomes associated with NIV and validate its safety
compared to immediate ETI, using the large Acute




This analysis was a retrospective study from ADHERE.
Participating sites were required to have institutional
review board approval to have data entered into the
registry. However, the data collection system was
designed so that informed consent was exempted, as
medical data were collected by retrospective chart
review alone and did not include any protocol-specified
treatment alteration. No patient identifiers were
included in the data registry.
Study Setting and Population
The ADHERE protocol continuously collected data
regarding the clinical characteristics, management, and
outcomes of patients hospitalized for ADHF (Diagnos-
tic-Related Group [DRG] 127) across the United States.
As of January 2006, ADHERE included more than 280
participating hospitals, with data from more than
200,000 hospitalization episodes. Patients were eligible
for inclusion into the ADHERE registry if they were at
least 18 years old, admitted to an acute care hospital,
and given a discharge diagnosis of acute heart failure
(DRG 127), or if acute heart failure was the principal
focus of treatment, and there was an accessible medical
record. Eligibility was not contingent on the use of any
specific therapeutic agent or regimen. Data were col-
lected by retrospective chart review and entered into a
Web-based data capture system via an electronic case
report form. Investigators and research coordinators at
individual sites identified patients and completed case
report forms for all consecutive patients meeting the
registry enrollment criteria. If a site had more than 75
enrollees per month, forms could be completed for a
random sample of consecutive patients. The registry
accumulated data on individual hospitalizations, not on
individual patients.
Our study reviewed all hospitalized heart failure
admissions admitted from the ED and entered into the
ADHERE database. We compared characteristics and
outcomes in the following cohorts: 1) no ventila-
tion—did not receive either NIV or ETI; 2) NIV
356 Tallman et al. • NONINVASIVE VENTILATION IN HF PATIENTS
success—received NIV and did not require any addi-
tional airway support; 3) NIV failure—received a trial of
NIV, but ultimately required ETI; and 4) ETI—individu-
als who received only ETI. The data were collected
between October 2001 and November 2004.
Study Protocol
Data on demographics (age, gender, race), medical his-
tory (if the patient had any of 17 cardiovascular dis-
eases), use of specific chronic medications (i.e., those
recommended by the Heart Failure Society of America),
clinical characteristics at initial presentation (e.g., vital
signs, electrocardiogram, laboratory, and x-ray data),
treatments received (e.g., any medication received in
the ED or hospital for the treatment of heart failure),
procedures performed (cardiopulmonary resuscitation
[CPR], defibrillation, cardiac catheterization, dialysis,
mechanical ventilation, or ultrafiltration), length of time
and hospital admission, clinical response to therapy,
and disposition were recorded using the information
collected from the discharge medical record. Data are
reported in aggregate format.
Data Analysis
The multivariable analysis included patients who
received ventilation support. This included initial use of
NIV, successful NIV use, unsuccessful NIV use and sub-
sequent intubation, and initial ETI without an NIV trial.
The goal of the study was not to identify the criteria
that determined which patients received NIV versus ETI
(once the decision was made to use ventilatory sup-
port); the focus was on successful NIV use and later to
determine the association with additional heart failure
treatments. Our study was not designed to find causal
relationships.
One-way analysis of variance or two-sided Wilcoxon
rank sum testing was performed for continuous data.
Chi-square tests were used for categorical data. Multi-
variable logistic regression was used to adjust mortality
comparisons in previously identified mortality risk fac-
tors12,13 and variables shown to be significantly different
between cohorts in the univariate analysis model. The
area under the receiver operator curve (AUC) was used
to assess model discrimination. Unadjusted and adjusted
odds ratios along with their corresponding 95% CI and
p-values are reported. All analyses were performed
using SAS Version 8.2 (SAS Institute, Cary, NC).
RESULTS
As of December 2004, the ADHERE database contained
147,362 records, with 114,756 (78%) cases of ADHF
admitted from the ED. Of ED patients, 37,372 (33%) had
procedure data, and ventilation was used in 2,430
(6.5%). If ventilated, 1,760 (72.4%) received NIV, and
670 (27.6%) had ETI without an NIV trial. In the NIV
cohort, 1,688 (95.9%) were managed only by NIV (NIV
success), while 72 (4.1%) failed NIV and subsequently
received ETI (NIV failure).
Demographics are presented in Table 1. The NIV fail-
ure group was younger and with more African Ameri-
cans than all other groups. Data of past medical history
are reported in Table 2. Higher rates of atrial fibrilla-
tion, COPD, and heart failure were reported in the NIV
success group compared to the ETI group (p < 0.05 for
all). More patients in the NIV failure group had liver
failure; otherwise, there were no differences in past
medical history compared to the ETI cohort.
Patients’ initial hemodynamic data are presented in
Table 3. NIV failures resembled the ETI group more
than NIV successes. Only presenting oxygen saturation
(SaO2) was different between NIV failure and ETI, with
the lowest level (84%) in the NIV failure cohort and the
highest in the NIV success (90%) patients. Indices of
volume overload were mixed between NIV success and
ETI; there were no differences in chest x-ray congestion
rates, but edema and rales were more frequent, and
dyspnea at rest less frequent, in the NIV success group.
Although not statistically significant, NIV failures had a
lower rate of abnormal troponin levels (7% vs. 13%)
than the ETI group. The most predictive parameters for
mortality (blood urea nitrogen [BUN], creatinine, and
systolic blood pressure [sBP])12,13 were similar among
all groups.
In regard to intravenous medications received dur-
ing hospitalization, there was less difference between
NIV failure and ETI than NIV successes and ETI
(Table 4), suggesting an appropriate increase in thera-
peutic intensity for patients failing airway manage-
ment. The NIV failure group received similar amounts
of inotropes, but more vasodilators (nitroglycerin in
particular) than patients in the ETI cohort. The NIV
group received vasoactives (any inotrope or vasodila-
tor) less often than ETI patients, except for nesiritide.
Since urgency of treatment is important in dyspnea, it
Table 1







ETI (n = 670)
Age (yr), mean ± SD 72.7 ± 14.2* 72.3 ± 14.3* 68.3 ± 14.0 71.0 ± 12.8
Gender (% male) 48.3* 42.4 47.2 43.2
Race (% African American) 21.5* 23.3 31.4 25.7
Race (% white) 73.8* 73 61.4 69.6
ETI = endotracheal intubation; NIV = noninvasive ventilation.
*p < 0.05. p-Values were calculated by one-way analysis of variance for continuous variables, and chi-square test for categorical
variables, by comparing each category to ETI.
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is noteworthy that there are no differences in time to
vasoactives among the ventilation groups. However,
both NIV success and NIV failures received intrave-
nous diuretics faster than the ETI group (18 minutes
vs. 36 minutes respectively).
Table 5 lists hospital procedures. Although not signif-
icantly different, NIV failures had less CPR, defibrilla-
tion, and dialysis than ETI. This observation continued
with decreasing illness severity, becoming significant in
the NIV success and no ventilation groups versus ETI.
In-hospital outcomes (Table 6) demonstrated stepwise
mortality increases when comparing no ventilation or
NIV to ETI. While no significant differences were found
between NIV failure and ETI, there was a trend for
increased length of stay (LOS) in NIV failures compared
to ETI.
Table 7 compares outcomes between no ventilation
and all NIV groups (successes and failures combined).
No ventilation patients had a lower severity of illness,
manifested by less premorbid medical history, higher
Table 2









Active malignancy 5.2 6.5 4.2 5.4
Atrial fibrillation 31.9 28.0 16.7 21.2
CAD 58.0 59.0 56.9 59.9
COPD ⁄ asthma 31.1 45.0 43.1 39.4
Cardiac valvular disease 21.5 18.8 18.1 19.6
Chronic dialysis 4.7 6.1 5.6 6.7
Chronic RI 30.3 33.2 27.8 31.5
Diabetes 44.4 50.3 48.6 50.9
History of HF 75.5 80.3 80.6 75.2
Hyperlipidemia ⁄ dyslipidemia 37.2 38.5 40.3 39.6
Hypertension 75.8 79.4 81.9 80.0
Liver disease 2.7 2.7 8.3 3.4
Pacemaker 18.8 14.9 11.1 11.3
Peripheral vascular disease 18.7 20.4 18.1 20.7
Prior MI 29.5 32.5 26.4 31.6
Stroke 17.0 16.9 13.9 19.6
Ventricular tachycardia ⁄ fibrillation 8.1 7.0 9.7 10.3
CAD = coronary artery disease; COPD = chronic obstructive pulmonary disease; ETI = endotracheal intubation; HF = heart failure;
MI = myocardial infarction; NIV = noninvasive ventilation; RI = renal insufficiency.
*All values listed as percentage of total cohort.
p < 0.05. p-Values were calculated by chi-square test by comparing each category to ETI.
Table 3









Congestion on first CXR (%) 73.9* 85.8 94.4 88.2
Dyspnea at rest (%) 31.9* 56.9* 69.4 64.5
Edema (%) 66.0* 67.4* 66.7 56.7
Elevated troponin (%) 6.2* 7.0* 7.4 13.3
Fatigue (%) 29.3* 28.9 30.6 25.1
Rales (%) 66.3* 78.8* 79.2 73.6
In- or pre-hospital LVEF < 40 or
moderate ⁄ severe impairment (%)
50.8 45.9* 55.9 54.6
In- or pre-hospital LVEF, mean 38.2 39.9* 36.5 36.9
O2 saturation, mean ± SD 94.2 ± 5.9* 89.6 ± 10.3* 84.0 ± 15.7* 88.1 ± 13.0
sBP (mm Hg), mean ± SD 143.7 ± 32.4* 156.6 ± 37.6 157.0 ± 38.7 153.8 ± 44.0
dBP (mmHg), mean ± SD 77.5 ± 19.8* 84.9 ± 24.3 88.4 ± 26.0 84.7 ± 27.2
BUN (mg ⁄ dL), mean ± SD 32.1 ± 20.9 32.0 ± 20.1 30.8 ± 20.6 32.1 ± 21.9
Creatinine (mg ⁄ dL), mean ± SD 1.8 ± 1.6* 1.9 ± 2.0 1.8 ± 1.5 2.1 ± 2.2
Sodium (mmol ⁄ L), mean ± SD 138.0 ± 4.6 138.2 ± 4.5 137.8 ± 4.4 138.4 ± 5.0
QRS duration (msec), mean ± SD 114.9 ± 34.3 113.5 ± 33.2 112.7 ± 30.9 115.0 ± 32.9
Heart rate (beats ⁄ min), mean ± SD 87.4 ± 21.4* 99.7 ± 25.0* 101.6 ± 26.9 103.0 ± 27.2
Hemoglobin (g ⁄ dL), mean ± SD 12.0 ± 2.1* 12.4 ± 2.2 13.0 ± 2.3 12.5 ± 2.4
BUN = blood urea nitrogen; CXR = chest x-ray; dBP = diastolic blood pressure; ETI = endotracheal intubation; LVEF = left ventric-
ular ejection fraction; NIV = noninvasive ventilation; sBP = systolic blood pressure.
*p < 0.05. p-Values were calculated by one-way analysis of variance for continuous variables and chi-square test for categorical
variables, by comparing each category to ETI.
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SaO2, less evidence of pulmonary congestion, and less
intravenous diuretics, vasodilators, and inotrope use.
Consequently, the no ventilation cohort had shorter
hospitalizations, fewer intensive care unit (ICU) admis-
sions, and lower mortality, although median ICU time
was slightly longer.
In-hospital deaths of NIV failure and ETI had similar
unadjusted rates (Table 8). Even after risk adjustment,
the mortality difference increased but did not reach sta-
tistical significance (multivariable logistic regression
model AUC = 0.74). Thus, the possibility of an adverse
effect of NIV failure cannot be completely excluded.
When comparing NIV success to ETI, even after adjust-
ment for previously identified mortality risk factors, the
NIV success cohort had significantly lower mortality.
DISCUSSION
To the best of our knowledge, this is the largest study
of NIV in patients with ADHF to date. We report find-
ings that more clearly define the population of ADHF
patients likely to receive NIV and their corresponding
outcomes compared to other patient cohorts. We found
that NIV is a commonly used intervention, and ADHF
patients selected for NIV are usually successfully man-
aged, as suggested by not requiring ETI. A small
minority of patients who received NIV ultimately
required ETI (72 ⁄ 1,760; 4.1%). Our data therefore sug-
gest that NIV is an effective strategy in the treatment of
ADHF.
Endotracheal intubation in hypoxic, critically ill,
hemodynamically unstable patients can be risky. This is
suggested by the fact that those undergoing immediate
ETI suffered the highest mortality of any group in our
analysis. An alternative, safer, and effective manage-
ment strategy is desirable. In this study, we describe a
trend of worsening outcomes, starting with the lowest
death rate in the no ventilation group, increasing
through both NIV groups, and highest in ETI cohort.
Our findings are inconsistent with prior studies sug-
gesting that NIV is potentially harmful in the setting of
ADHF.8–10,14
Several theoretical concerns have been proposed with
NIV in addition to the inherent risk of barotrauma from
all types of positive pressure ventilation. With elevated
intrathoracic pressure, increased resistance to ven-
tricular ejection occurs. This is probably of little con-
sequence in the normal heart, but in a failing
myocardium, an increased workload can decrease car-
diac output. For example, in atrial fibrillation treated
with CPAP, a decline in left ventricular ejection fraction
(LVEF), especially in the setting of low systemic vascular
resistance (SVR), occurs.14 This suggests that the hemo-
dynamic impact of NIV in ADHF may be significant.
Table 4










Any diuretics (%) 88.9* 92.9 94.4 92.1
Any vasoactives (%) 30.3* 52.4* 81.9 72.7
Any inotropes (%) 9.2* 11.9* 34.7 39.4
Dobutamine (%) 4.5* 4.6* 12.5 14.2
Dopamine (%) 4.8* 8.9* 27.8 30.4
Milrinone (%) 2.1* 1.4* 6.9 4.5
Any vasodilators (%) 25.0* 46.3* 68.1* 54.3
Nesiritide (%) 19.1* 25.1 29.2 28.5
Nitroglycerin (%) 7.3* 29.1* 45.8* 34.0
Nitroprusside (%) 0.5* 1.0* 5.6 3.6
Hours to first diuretic, median 2.6* 1.0* 0.7 1.3
Hours to first vasoactive, median 5.5* 1.2 1.2 1.6
ETI = endotracheal intubation; NIV = noninvasive ventilation.
*p < 0.05. p-Values were calculated by Wilcoxon test for continuous variables and chi-square test for categorical variables, by












CPR 0.9* 1.1* 5.6 11.2
Defibrillation 0.7* 0.8* 0 4.0
Cardiac catheterization 8.7* 8.8* 19.4 18.4
Dialysis 6.1* 7.7 6.9 9.7
Dialysis (begun during
index hospitalization)
1.7* 1.9* 1.4 3.3
Ultrafiltration 2.8 3.7 4.2 3.7
ETI = endotracheal intubation; CPR = cardiopulmonary resuscitation; NIV = noninvasive ventilation.
*p < 0.05. p-Values were calculated by a chi-square test by comparing each category to ETI; all values are percentages.
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Normally, a decline in cardiac output is compensated
for by neurohormonally mediated increases in SVR.
This is well tolerated in normal hearts; in heart failure
(HF), increased SVR further exacerbates the cardiac
output deficit. Carbon dioxide retention leads to respi-
ratory acidosis with the potential for adverse cardiac
effects. Ultimately, increasing SVR causes a decrease in
cardiac output, which triggers reflexive SVR increases
and further decreased cardiac output occurs. If
untreated, this spiral ends with cardiogenic shock and
death. One trial of 40 patients compared BiPAP and
low-dose isosorbide dinitrate (NIV group) to high-dose
isosorbide dinitrate (no NIV group).10 NIV patients had
higher rates of ETI and death, lower SaO2, and higher
composite endpoints of death, myocardial infarction
(MI), or ETI. Another analysis comparing BiPAP and
CPAP was terminated early because of a marked
increase in the rate of MI in the BiPAP cohort. Unfortu-
nately, the major limitation of this study was that it
lacked a standard therapy cohort.15
In contrast to these reports, two recent meta-analyses
of NIV in ADHF suggest a potential benefit. Although
neither analysis exceeds 300 patients, several unproven
theories support their conclusions. These include the
fact that positive pressure improves oxygenation by
increasing the numbers of expanded alveoli, the fact
that increased intraalveolar pressure physically drives
fluid into capillaries across alveolar membranes (thus
improving pulmonary gas exchange), the fact that by
using NIV the work of breathing is decreased, and the
fact that increasing intrathoracic pressure decreases












Mortality (%) 3.2* 7.9* 13.9 15.4
Admitted to ICU (%) 13.0* 38.9* 88.9 89.3
Median ICU LOS (days) 2.3* 2.0* 3.2 3.1
Median hospital LOS (days) 4.2* 4.6* 8.1 6.5
Discharged asymptomatic (%) 46.0 46.4 40.7 43.1
ETI = endotracheal intubation; ICU = intensive care unit; LOS = length of stay; NIV = noninvasive ventilation.
*p < 0.05. p-Values were calculated by Wilcoxon test for continuous variables and chi-square test for categorical variables, by
comparing each category to ETI.
Table 7






Active malignancy 5.2 6.4*
Atrial fibrillation 31.9 27.5*
COPD ⁄ Asthma 31.1 44.9*
Cardiac valvular disease 21.5 18.8*
Chronic dialysis 4.7 6.1*
Chronic RI 30.3 33.0*
Diabetes 44.4 50.2*
History of HF 75.5 80.3*
Hypertension 75.8 79.5*
Pacemaker 18.8 14.8*
Prior MI 29.5 32.3*
Signs of congestion
CXR with congestion 73.9 86.2*
Rest dyspnea 31.9 57.4*
Rales 66.3 78.8*
Presentation findings
sBP (mm Hg), mean 143.7 156.7*
Initial O2 saturation (%), mean 94.2 89.4*
Creatinine (mg ⁄ dL), mean 1.8 1.9*






Median time to diuretic (hr) 2.6 1.0*
Median time to first
vasoactive (hr)
5.5 1.2*
Hospital procedures ⁄ outcomes
Dialysis 6.1 7.7*
Median hospital LOS (days) 4.2 4.8*
Admitted to ICU (%) 13.0 40.9*
Median ICU time (days) 2.3 2.1*
Mortality (%) 3.2 8.1*
COPD = chronic obstructive pulmonary disease; CXR = chest
x-ray; HF = heart failure; HR = heart rate; ICU = intensive care
unit; IV = intravenous; LOS = length of stay; MI = myocardial
infarction; NIV = noninvasive ventilation; RI= renal insuffi-
ciency; sBP = systolic blood pressure.
*p < 0.05. p-Values were calculated for continuous variables
by one-way analysis of variance or Wilcoxon test and for
categorical variables by a chi-square test. All values are





Mortality (95% CI) p-Value
NIV failure vs. ETI 0.89 (0.44, 1.79) 0.74
NIV failure vs. ETI* 1.43 (0.66, 3.08) 0.37
NIV success vs. ETI* 0.51 (0.37, 0.69) < 0.0001
CI = confidence interval; ETI = endotracheal intubation;
NIV = noninvasive ventilation.
*Risk adjustment for previously defined risk factors of age,
blood urea nitrogen, systolic and diastolic blood pressure,
creatinine, sodium, heart rate, dyspnea at rest, and factors
significantly different between the two groups (liver disease,
intravenous vasodilator use, in-hospital use of antiarrhyth-
mics or angiotensin receptor blockers, and oxygen satura-
tion.
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In our analysis, a therapeutic trial of NIV produced
no worse outcomes than immediate ETI in terms of
mortality, ICU LOS, overall hospital LOS, or asymptom-
atic discharge. However, although statistically insignifi-
cant, the median hospital LOS was longer for NIV
failures. There was a nonsignificant increase in mortal-
ity in the NIV group.
In examining the LOS, several trends are apparent.
Patients receiving no NIV had lower rates of ICU
admissions, but if admitted to the ICU, had a longer
LOS than those receiving NIV. Why this occurs is
unclear, but may be related to the consequence of
unclear initial presentations resulting in therapeutic
delays or acute decompensation occurring after hospi-
talization. Also unexplained is the nonsignificant trend
for patients receiving NIV and ETI requiring longer
overall LOS than the cohort undergoing ETI only.
Although early death in the ETI cohort could have
explained these results, the median LOS for patients
alive at discharge showed similar trends (8.8 days vs.
6.9 days for NIV failure vs. ETI, p > 0.05, respectively).
Our results suggest several clinical opportunities.
Acute pulmonary edema with severe respiratory dis-
tress can be transient, representing an imbalance of
hemodynamics rather than pure volume overload. In
this situation, aggressive ED management with therapy
directed at correcting the mismatch between excessive
SVR and decreased cardiac output may allow sufficient
time for some patients to improve. This is supported by
data from several risk stratification analyses; patients
with the highest presenting blood pressures were most
likely to have successful management (defined as dis-
charge within 24 hours and no rehospitalization within
30 days).16,17 By temporarily obviating the need for ETI,
a short course of NIV may improve outcomes by allow-
ing hemodynamic interventions (such as lowering blood
pressure) time to become effective. NIV is not definitive
therapy, but is a temporizing measure to avoid ETI
while initiating definitive therapy. It is possible that if
used with inadequate10 or absent concomitant medical
therapy, NIV outcomes could be worse than ETI alone.
To the best of our knowledge, we present data from
the largest cohort of NIV and ADHF patients to date
and suggest that in selected patients, it is reasonable to
attempt a closely monitored trial of NIV prior to ETI. If
unsuccessful, ETI may proceed without significantly
worsening outcomes beyond that expected from imme-
diate ETI. However, it is important to note that a signifi-
cant number of patients in this analysis were deemed to
require immediate ETI (28% of patients on respiratory
support), and we cannot comment on the value of NIV
in this cohort. In the absence of specific recommenda-
tions, selection of patients most likely to be successfully
treated with NIV is based on clinical judgment. Our data
show that if it was possible to avoid immediate ETI in
ADHF, patients receiving NIV had significantly better
outcomes, with lower rates of cardiopulmonary resusci-
tation and defibrillation, decreased ICU LOS, and fewer
deaths. Beyond the existing small studies that were not
powered to demonstrate small mortality trends, the size
of this observation database provides reassurances that
NIV is not associated with increased mortality in
patients with ADHF.
LIMITATIONS
This analysis is an examination of a large retrospective
data set and cannot determine cause and effect. It is
important to recognize that physicians apply a selection
bias when choosing NIV or immediate ETI for ADHF.
The small number of NIV failures (less than 5%) is con-
sistent with a high degree of accuracy in selecting the
appropriate patient. We must also note that a signifi-
cant number of patients required immediate ETI (28%),
and we cannot comment on the value of NIV in this
cohort. Additionally, although it appears that ETI
patients had a greater severity of illness, as judged by
the increased risk of adverse outcomes, we cannot
ascertain if the selection of patients for immediate ETI
was accurate or appropriate. Some who received
immediate ETI may have been successfully managed
with NIV. However, with the suggestion that a trial of
NIV did not significantly increase risk in ADHF, a pro-
spective analysis to determine if NIV improves out-
comes can be reasonably performed.
Alternatively, our results could potentially be biased
by the consequence of a decreased severity of illness in
the NIV success cohort, where physicians used NIV in
patients who did not require it. This is not supported
by the demographic, initial presentation, or chronic
treatment data (Tables 1–5). While there were signifi-
cant differences in the medical history, four of the five
parameters were actually worse in the NIV success
cohort, compared to ETI. Furthermore, in another
ADHERE analysis examining findings associated with
acute mortality, an initial BUN > 43 mg ⁄ dL,
sBP < 115 mm Hg, or creatinine exceeding 2.7 mg ⁄ dL
was the most important predictor of death;12,13 there
was no difference between the NIV success and the ETI
groups. Finally, while troponin elevation has been
reported to be more prevalent in NIV,10,15 our analysis
found it elevated more often in the ETI group.
Of patients failing NIV, duration of therapy was vari-
able due to subjective judgment by the provider. The
timing of actual initiation of NIV or ETI was not fixed
and was at the discretion of the treatment physician.
This makes timing a limitation. Furthermore, patients
captured in this study were in different locations in the
hospital, not just localized to the ED or observation
unit. Procedures were done in the ED, and there are no
available details on specific timing or duration.
This study describes the overall pattern of ventilatory
support used in ADHF patients in the ADHERE centers.
There is no attempt to describe the indications used to
determine use of any therapy, including ventilatory sup-
port. Thus, based on our data, it is inappropriate to
conclude that any specific treatment options are more
or less safe or more or less effective than another.
CONCLUSIONS
Noninvasive ventilation is an airway adjunct that may
be useful in heart failure patients with severe respira-
tory distress and dyspnea. When used in selected indi-
viduals, it is frequently successful at avoiding ETI.
Furthermore, in those successfully managed with NIV,
outcomes may be better than in patients undergoing
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immediate ETI. Although caution should be utilized in
patient selection, NIV may be a reasonable treatment
option in ADHF.
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